Moderna, Inc.
MRNA
NASDAQ·Healthcare·Biotechnology·Mkt cap $57.8B
$145.55
▼ -2.23%
P/E
-18.24
Mkt Cap
$57.8B
52-Wk Range
$22.28–$176.66
52-Week Range
$22.28 - $176.66
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 486.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary mRNA technology platform
- Rapid vaccine development capabilities
- Diverse therapeutic portfolio
- Strong research and development infrastructure
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Expanding global vaccine markets
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+205.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MRNA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
JUL 31, 2026
Reported EPS of -$1.97 vs -$2.03 consensus (+3.0% surprise). Revenue of $145.0M vs $102.9M expected (+40.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+3.0%
Revenue trend · last 8Q
—
-66%
-36%
-36%
-45%
-29%
+264%
+2%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.9B
$956.0M
$107.0M
$142.0M
$1.0B
$678.0M
$389.0M
$145.0M
Margins · last 8Q
Gross
35.9%
Operating
—
Profit
-539.3%
Wall Street consensus
18 analysts · 44% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
44%
Hold
44%
Sell
11%
Median Price Target
$150.00
▲ +3.1% vs $145.55
Latest: UBS · Sep 3, 2026
1 analyst covering
vs Industry
How MRNA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related